OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Neurology is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?	1637
Technology of deep brain stimulation: current status and future directions	477
Recovery from disorders of consciousness: mechanisms, prognosis and emerging therapies	365
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	335
Maternal immune activation and neuroinflammation in human neurodevelopmental disorders	309
Diagnosis and management of migraine in ten steps	275
Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease	225
Prodromal Parkinson disease subtypes — key to understanding heterogeneity	213
Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus	205
Developing the ATX(N) classification for use across the Alzheimer disease continuum	183
Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits	182
Cycles in epilepsy	173
Synaptic degeneration in Alzheimer disease	172
Improving clinical trial outcomes in amyotrophic lateral sclerosis	170
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic	161
Advances in local therapy for glioblastoma — taking the fight to the tumour	159
Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration	155
Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours	149
Neurological infection with SARS-CoV-2 — the story so far	148
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility	146
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies	143
The effects of the COVID-19 pandemic on people with dementia	141
The human connectome in Alzheimer disease — relationship to biomarkers and genetics	135
Stroke in Africa: profile, progress, prospects and priorities	131
Circadian rhythms in neurodegenerative disorders	124

Global epidemiology of migraine and its implications for public health and health policy	123
The inter-relationship between delirium and dementia: the importance of delirium prevention	115
Human cerebral organoids — a new tool for clinical neurology research	112
The metabolic basis of epilepsy	108
Apparent changes in the epidemiology and severity of multiple sclerosis	107
Single-cell and spatial transcriptomics: deciphering brain complexity in health and disease	98
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis	97
Psychosis in Alzheimer disease — mechanisms, genetics and therapeutic opportunities	97
The neuroanatomical–functional paradox in spinal cord injury	96
Non-neuronal cells in amyotrophic lateral sclerosis — from pathogenesis to biomarkers	96
Hypomyelinating leukodystrophies — unravelling myelin biology	95
Pharmacological brain cytoprotection in acute ischaemic stroke — renewed hope in the reperfusion era	92
The importance of ongoing international surveillance for Creutzfeldt–Jakob disease	91
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease	89
Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics	86
Sex and gender in neurodevelopmental conditions	82
Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials	81
Amyloid-β: a potential link between epilepsy and cognitive decline	78
White matter injury in infants with intraventricular haemorrhage: mechanisms and therapies	78
Neurobehavioural comorbidities of epilepsy: towards a network-based precision taxonomy	76
Changing demography and the challenge of dementia in India	75
The role of glial cells in multiple sclerosis disease progression	74
Alzheimer disease in African American individuals: increased incidence or not enough data?	72
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	72
Aducanumab and the FDA — where are we now?	71
Bruton tyrosine kinase inhibitors for multiple sclerosis	71
Astrocytes in the initiation and progression of epilepsy	71
Can we learn lessons from the FDA’s approval of aducanumab?	71
The role of the gut microbiota in multiple sclerosis	70
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies	69
Identification of clinically relevant biomarkers of epileptogenesis — a strategic roadmap	69
Tau-targeting therapies for Alzheimer disease: current status and future directions	64
Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease	63
A global view of the genetic basis of Alzheimer disease	63
Cluster headache pathophysiology — insights from current and emerging treatments	62
Early-stage Alzheimer disease: getting trial-ready	62
The multiple sclerosis prodrome	61
Mind the gap: from neurons to networks to outcomes in multiple sclerosis	54
Hormonal influences in migraine — interactions of oestrogen, oxytocin and CGRP	53
Nuclear pore complexes — a doorway to neural injury in neurodegeneration	53
Autonomic manifestations of epilepsy: emerging pathways to sudden death?	52
The neurovascular unit and systemic biology in stroke — implications for translation and treatment	52
Social determinants of health in multiple sclerosis	52
Rapidly progressive dementias — aetiologies, diagnosis and management	50
MRI biomarkers in neuro-oncology	49
The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA	48
Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?	46
Genetics of common cerebral small vessel disease	46
Cognitive impairment in people living with HIV: consensus recommendations for a new approach	45
Neurofilaments as biomarkers in neurological disorders — towards clinical application	45

Review and update of the concept of embolic stroke of undetermined source	45
Perinatal stroke: mapping and modulating developmental plasticity	43
Guillain–Barré syndrome in low-income and middle-income countries: challenges and prospects	42
Closing the loop for patients with Parkinson disease: where are we?	41
Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes	41
Global synergistic actions to improve brain health for human development	39
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	39
Inflammation in multiple sclerosis: consequences for remyelination and disease progression	38
Multifaceted microglia — key players in primary brain tumour heterogeneity	38
Positron emission tomography in multiple sclerosis — straight to the target	37
From the prodromal stage of multiple sclerosis to disease prevention	37
Refining oxytocin therapy for autism: context is key	37
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	36
hiPSCs for predictive modelling of neurodegenerative diseases: dreaming the possible	35
Functional brain networks in the evaluation of patients with neurodegenerative disorders	35
Emerging therapies to target CNS pathophysiology in multiple sclerosis	34
Molecular biomarkers for vascular cognitive impairment and dementia	34
Prospective memory impairment in neurological disorders: implications and management	33
Applying genomic and transcriptomic advances to mitochondrial medicine	33
Lecanemab trial in AD brings hope but requires greater clarity	33
Dissecting the complexities of Alzheimer disease with in vitro models of the human brain	32
Maximizing treatment efficacy through patient stratification in neuropathic pain trials	30
Vaccination and immunotherapies in neuroimmunological diseases	30
Why functional neurological disorder is not feigning or malingering	29
Epigenetic genes and epilepsy — emerging mechanisms and clinical applications	28
Schizophrenia: from neurochemistry to circuits, symptoms and treatments	27
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	27
Genetic testing in dementia — utility and clinical strategies	27
Neurogenetic disorders across the lifespan: from aberrant development to degeneration	26
Neuroprognostication: a conceptual framework	26
Biomarker-based staging of Alzheimer disease: rationale and clinical applications	26
Adaptive and maladaptive myelination in health and disease	26
Origins and immunopathogenesis of autoimmune central nervous system disorders	25
Neuropsychology’s race problem does not begin or end with demographically adjusted norms	25
Cognitive impairment and World Trade Centre-related exposures	24
Facing the urgency of therapies for progressive MS — a Progressive MS Alliance proposal	24
A cultural approach to dementia — insights from US Latino and other minoritized groups	23
Headache in people with epilepsy	23
Gene therapy for primary mitochondrial diseases: experimental advances and clinical challenges	23
Neurodegenerative diseases associated with non-coding CGG tandem repeat expansions	23
Viral pathogens increase risk of neurodegenerative disease	23
Linking the cerebellum to Parkinson disease: an update	22
Genetic generalized epilepsies in adults — challenging assumptions and dogmas	22
Pathogenic autoantibodies in multiple sclerosis — from a simple idea to a complex concept	22
The amyotrophic lateral sclerosis exposome: recent advances and future directions	22
Inequities in neurology amplified by the COVID-19 pandemic	22
Pain-resolving immune mechanisms in neuropathic pain	21
Is Alzheimer disease a disease?	21
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	21
Neurological telemedicine in the COVID-19 era	21
Myasthenia gravis: the changing treatment landscape in the era of molecular therapies	19
The childhood migraine syndrome	18
Addressing disparities in the global epidemiology of stroke	18
Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis	18
Counting the neurological cost of COVID-19	18
Recessive cerebellar and afferent ataxias — clinical challenges and future directions	18
SARS-CoV-2 detected in olfactory neurons	17
Redefining cerebral palsies as a diverse group of neurodevelopmental disorders with genetic aetiology	17
Epilepsy and epileptiform activity in late-onset Alzheimer disease: clinical and pathophysiological advances, gaps and conundrums	15
Nutritional and metabolic factors in amyotrophic lateral sclerosis	15
Idiopathic intracranial hypertension: a step change in understanding the disease mechanisms	15
The challenges of anti-tau therapeutics in Alzheimer disease	15
Cell-based therapies for neurological disorders — the bioreactor hypothesis	14
Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases	13
Isoform-dependent APOE secretion modulates neuroinflammation	13
Neuropsychological impairment in amyotrophic lateral sclerosis–frontotemporal spectrum disorder	13
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	12
Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management	12
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	11
Towards a global view of multiple sclerosis genetics	11
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	11
Multifaceted roles of APOE in Alzheimer disease	11
Brain changes after COVID-19 — how concerned should we be?	10
Cohort-guided insights into gene–environment interactions in autism spectrum disorders	10
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	10
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease	10
Getting specific: targeting Fc receptors in myasthenia gravis	10